Ergoteles’s Valion Bio VBIO Stock Holding History

Ergoteles’s Portfolio VBIO Stock Details VBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-17	Closed	-$4.28K	–	1525
2023 Q1	$4.28K	Buy	+17	New	+$11.9K	﹤0.01%	1185
2022 Q1	–	Sell	-10	Closed	-$68K	–	1630
2021 Q4	$68K	Buy	+10	New	+$73.3K	﹤0.01%	1172

Other funds holding VBIO

SSWM

Sheets Smith Wealth Management Winston-Salem, North Carolina $1B AUM 29.77% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

CSS

Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return

OGC

One68 Global Capital New York $30.9M AUM

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Ergoteles's VBIO Position: Q2 2023 in Review

Ergoteles sold out of Valion Bio (VBIO) in Q2 2023, closing a stake of 17 shares — an estimated $4.28K sold.

Ergoteles first reported a position in VBIO in Q4 2021 and held it in 2 quarters. The position peaked at $68K in Q4 2021. 11 funds tracked by Wall St. Rank hold VBIO as of Q2 2023.

Ergoteles reported no remaining Valion Bio position as of Q2 2023 after selling out during the quarter.
Ergoteles sold 17 Valion Bio shares in Q2 2023, an estimated $4.28K.
Ergoteles first reported a position in Valion Bio in Q4 2021 and held it in 2 quarters.
Ergoteles's Valion Bio position peaked at $68K in Q4 2021.
11 funds tracked by Wall St. Rank held Valion Bio as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.